NASDAQ:BLPH - Bellerophon Therapeutics Stock Price, Forecast & News

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics shares reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

Bellerophon Therapeutics Inc (NASDAQ:BLPH) released its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.90) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.10) by $0.20. View Bellerophon Therapeutics' Earnings History.

Bellerophon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Bellerophon Therapeutics.

2 brokerages have issued 1-year price targets for Bellerophon Therapeutics' stock. Their forecasts range from $30.00 to $30.00. On average, they expect Bellerophon Therapeutics' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 225.9% from the stock's current price. View Analyst Price Targets for Bellerophon Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellerophon Therapeutics.

Press coverage about BLPH stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bellerophon Therapeutics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Bellerophon Therapeutics.

Bellerophon Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 359,600 shares, a decrease of 7.8% from the January 15th total of 390,200 shares. Based on an average daily volume of 539,300 shares, the short-interest ratio is presently 0.7 days. Currently, 0.7% of the shares of the stock are sold short. View Bellerophon Therapeutics' Current Options Chain.

Some companies that are related to Bellerophon Therapeutics include SCYNEXIS (SCYX), Tiziana Life Sciences (TLSA), Advaxis (ADXS), NewLink Genetics (NLNK), Soligenix (SNGX), Aclaris Therapeutics (ACRS), Alpine Immune Sciences (ALPN), DiaMedica Therapeutics (DMAC), American Brivision (Holding) (ABVC), Processa Pharmaceuticals (PCSA), Bellicum Pharmaceuticals (BLCM), Leap Therapeutics (LPTX), Aridis Pharmaceuticals (ARDS), Acasti Pharma (ACST) and Q BioMed (QBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Onconova Therapeutics (ONTX), Aurinia Pharmaceuticals (AUPH), AVEO Pharmaceuticals (AVEO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Biopharmx (BPMX), BIOLINERX LTD/S (BLRX), Sorrento Therapeutics (SRNE) and Rexahn Pharmaceuticals (REXN).

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (36.65%) and Virtu Financial LLC (0.11%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang. View Institutional Ownership Trends for Bellerophon Therapeutics.

BLPH stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Virtu Financial LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang. View Insider Buying and Selling for Bellerophon Therapeutics.

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLPH stock can currently be purchased for approximately $9.21.

Bellerophon Therapeutics has a market capitalization of $42.16 million. The biotechnology company earns $2.81 million in net income (profit) each year or ($5.10) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.View Additional Information About Bellerophon Therapeutics.

The official website for Bellerophon Therapeutics is http://www.bellerophon.com/.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]